mRNA-3705
Phase 2Active 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Methylmalonic Acidemia
Conditions
Methylmalonic Acidemia
Trial Timeline
Aug 6, 2021 → Jul 1, 2028
NCT ID
NCT04899310About mRNA-3705
mRNA-3705 is a phase 2 stage product being developed by Moderna for Methylmalonic Acidemia. The current trial status is active. This product is registered under clinical trial identifier NCT04899310. Target conditions include Methylmalonic Acidemia.
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05295433 | Phase 2 | Recruiting |
| NCT04899310 | Phase 2 | Active |
Competing Products
4 competing products in Methylmalonic Acidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-3705 | Moderna | Phase 2 | 0 |
| "The MaP Study": Mapping the Patient Journey in MMA and PA | Moderna | Preclinical | 0 |
| mRNA-3704 | Moderna | Phase 2 | 0 |
| Carglumic Acid | Recordati | Pre-clinical | 30 |